Cargando…

Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion

INTRODUCTION: Alzheimer’s disease (AD) is the most common cause of dementia worldwide, making it a major public health issue. Anti-amyloid and anti-tau antibodies are the most advanced therapeutic approach at present. Three drugs (lecanemab, donanemab and aducanumab) are on track to be marketed in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Esquer, Arthur, Blanc, Frédéric, Collongues, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10630258/ https://www.ncbi.nlm.nih.gov/pubmed/37812325 http://dx.doi.org/10.1007/s40120-023-00541-1

Ejemplares similares

Moving Away from Amyloid Beta to Move on in Alzheimer Research
por: Moreno-Treviño, María G., et al.
Publicado: (2015)

Comparison of Tau and Amyloid-β Targeted Immunotherapy Nanoparticles for Alzheimer’s Disease
por: Mashal, Yara, et al.
Publicado: (2022)

Immunotherapy for the treatment of Alzheimer’s disease: amyloid-β or tau, which is the right target?
por: Castillo-Carranza, Diana L, et al.
Publicado: (2013)

Placebo effects in allergen immunotherapy: an experts’ opinion
por: Frew, Anthony J., et al.
Publicado: (2018)

Expert opinions on immunotherapy for patients with colorectal cancer
por: Wang, Feng, et al.
Publicado: (2020)

CXCR4 as a novel target in immunology: moving away from typical antagonists
por: Caspar, Birgit, et al.
Publicado: (2022)

Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
por: Song, Chenghuan, et al.
Publicado: (2022)

Computing - moving away from the mainframe
Publicado: (1994)

Looking away from a moving target does not disrupt the way in which the movement toward the target is guided
por: Cámara, Clara, et al.
Publicado: (2020)

Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
por: Plotkin, Steven S., et al.
Publicado: (2020)

Live operative workshops: Should we do away with them?
por: Kittur, Dinesh H.
Publicado: (2012)

Live operative workshops: Should we do away with them?
por: Chandrasekharam, V. V. S., et al.
Publicado: (2013)

Erdheim-Chester disease, moving away from the orphan diseases: A case report
por: Stempel, Jessica M., et al.
Publicado: (2016)

Crohn’s Strictures—Moving Away from the Knife
por: Stenke, Emily, et al.
Publicado: (2017)

Moving away from zero COVID in China
por: Burki, Talha
Publicado: (2023)

How should we regulate products of new breeding techniques? Opinion of surveyed experts in plant biotechnology
por: Lassoued, Rim, et al.
Publicado: (2020)

Small molecules to target tau amyloid aggregation
por: Manglano-Artuñedo, Zoe, et al.
Publicado: (2023)

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer’s disease
por: Lambracht-Washington, Doris, et al.
Publicado: (2013)

Are researchers moving away from animal models as a result of poor clinical translation in the field of stroke? An analysis of opinion papers
por: Pound, Pandora, et al.
Publicado: (2020)

Who should provide expert opinion in emergency medicine‐related medical litigation?
por: Dalling, Julie, et al.
Publicado: (2022)

Experts Opinion
por: Goldberg, Ivan, et al.
Publicado: (2012)

Expert Opinion
Publicado: (1920)

Editorial: Targets for Disease-Modifying Therapies in Alzheimer’s Disease, Including Amyloid β and Tau Protein
por: Parums, Dinah V.
Publicado: (2021)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)

Understanding Dupuytren's Disease Using Systems Biology: A Move Away from Reductionism
por: Rehman, Samrina, et al.
Publicado: (2012)

Computing - moving away from the mainframe by David Williams
Publicado: (1994)

Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets
por: Fišar, Zdeněk
Publicado: (2022)

Advances and considerations in AD tau-targeted immunotherapy
por: Bittar, Alice, et al.
Publicado: (2019)

Biomarkers for immunotherapy in bladder cancer: a moving target
por: Aggen, David H., et al.
Publicado: (2017)

Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer’s disease: an expert opinion and practical guideline
por: Filippi, Massimo, et al.
Publicado: (2023)

Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
por: Moreth, Jens, et al.
Publicado: (2013)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

More Expert Opinion
Publicado: (1920)

Amyloid Beta and Tau Proteins as Therapeutic Targets for Alzheimer's Disease Treatment: Rethinking the Current Strategy
por: Mondragón-Rodríguez, Siddhartha, et al.
Publicado: (2012)

Interacting Models of Amyloid-β and Tau Proteins: An Approach to Identify Drug Targets in Alzheimer’s Disease
por: Priya, Khadgawat, et al.
Publicado: (2021)

Can Laboratories Move Away from Single-Use Plastic?
por: Howes, Laura
Publicado: (2019)

Oligomeric tau-targeted immunotherapy in Tg4510 mice
por: Schroeder, Sulana, et al.
Publicado: (2017)

Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?
por: Bermejo, Sheila, et al.
Publicado: (2022)

Status of etoricoxib in the treatment of rheumatic diseases. Expert panel opinion
por: Kwiatkowska, Brygida, et al.
Publicado: (2017)

Pneumococcal Disease in High-Risk Adults in Lebanon: Expert Opinion
por: Bizri, Abdulrahman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_c5glu7ajgpahqo5tfsa477phe4